Israel - English - Ministry of Health

tzamal bio-pharma ltd - urokinase - powder for solution for injection - urokinase 250000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - urokinase - powder for solution for injection - urokinase 500000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - ganciclovir as sodium - powder for solution for infusion - ganciclovir as sodium 500 mg - ganciclovir - cymevene iv is indicated for the treatment of cmv retinitis in immunocompromised patiens, including patients with acquired immunodeficiency syndrome (aids). cymevene iv is also indicated for the prevention of cmv disease in transplant recipients at risk for cmv disease.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - busulfan - solution for injection - busulfan 60 mg / 10 ml - busulfan - busulfan - for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - busulfan - solution for injection - busulfan 60 mg / 10 ml - busulfan - for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israel - English - Ministry of Health

tzamal bio-pharma ltd - clomipramine hydrochloride - tablets slow release - clomipramine hydrochloride 75 mg - clomipramine - clomipramine - depression of varying origin: in children and adolescents there is not sufficient evidence of safety and efficacy of anafranil in the treatment of depressive states of varying aetiology and symptomatology. the use of anafranil in children and odolescents ( 0 - 17 years of age ) in this indication is therefore not recommended. obsessive compulcive syndromes: no experience is available in children younger than 5 years of age.